Premium Nahrungsergänzungsmittel | artgerecht

Belimumab – Uses, Mechanism and Side Effects

Belimumab is a monoclonal antibody used to treat systemic lupus erythematosus and lupus nephritis in adults and children aged 5 and older.

Regular tips about health Regular tips about health

Things worth knowing about "Belimumab"

Belimumab is a monoclonal antibody used to treat systemic lupus erythematosus and lupus nephritis in adults and children aged 5 and older.

What is Belimumab?

Belimumab is a monoclonal antibody belonging to the class of biologics. It is approved for the treatment of systemic lupus erythematosus (SLE) and active lupus nephritis (kidney inflammation caused by lupus). Marketed under the brand name Benlysta, it has received approval from both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). Belimumab can be used in adults and in children from the age of 5 years.

Mechanism of Action

Belimumab selectively inhibits the B-lymphocyte stimulator protein (BLyS), also known as BAFF (B-cell activating factor). This protein plays a key role in the survival, proliferation, and maturation of B-lymphocytes – the immune cells responsible for producing antibodies.

In patients with SLE, BLyS levels are often abnormally elevated, leading to excessive immune activation and the overproduction of autoantibodies that attack the body's own tissues. By blocking BLyS, belimumab reduces the number and activity of these misdirected B-cells, thereby dampening the autoimmune response and helping to prevent organ damage.

Indications

Systemic lupus erythematosus (SLE): In adults and children aged 5 years and above with active, autoantibody-positive disease that is inadequately controlled despite standard therapy.
Active lupus nephritis: In adults receiving standard background therapy.

Administration and Dosage

Belimumab is available in two formulations:

Intravenous infusion (IV): 10 mg/kg body weight, administered in a clinical setting over 1 hour. Initial doses are given at weeks 0, 2, and 4, followed by monthly infusions thereafter.
Subcutaneous injection (SC): 200 mg once weekly, self-administered by the patient after appropriate training.

The choice of administration route depends on the individual clinical situation and the treating physician's recommendation. Belimumab is always used as an add-on to existing standard therapy, such as hydroxychloroquine, corticosteroids, or immunosuppressants.

Side Effects

As with all biologics, belimumab can cause side effects. Common adverse effects include:

Upper respiratory tract infections (e.g., common cold, bronchitis)
Urinary tract infections
Nausea and diarrhea
Injection site reactions (with subcutaneous use)
Infusion-related reactions (with intravenous use)
Sleep disturbances and depressive episodes (in some cases)

Rare but serious risks include:

Severe infections, including opportunistic infections
Increased risk of progressive multifocal leukoencephalopathy (PML)
Suicidal ideation and psychiatric changes
Severe hypersensitivity reactions

Contraindications and Precautions

Belimumab should not be used in patients with:

Known severe hypersensitivity to the active substance
Active severe infections
Concurrent use of other biologics or cyclophosphamide (except in lupus nephritis where benefit may outweigh risk, as determined by a physician)

Use during pregnancy should only be considered if the potential benefit outweighs the risk to the fetus. Women of childbearing potential should use effective contraception during treatment and for at least 4 months after the last dose.

References

European Medicines Agency (EMA): Benlysta (belimumab) – Summary of Product Characteristics and European Public Assessment Report (EPAR). Available at: https://www.ema.europa.eu
Navarra S et al. – Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. The Lancet. 2011;377(9767):721-731.
Furie R et al. – Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. New England Journal of Medicine. 2020;383(12):1117-1128.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.